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1. Introduction 
1.1 Pseudomonas aeruginosa 
1.1.1. Microbiology 
 
Pseudomonas aeruginosa (P. aeruginosa) was first extracted from green pus and 
described by French pharmacist Gessard in 1882 (1). This bacterium belongs to the 
family of Pseudomonadaceae. It is a gram-negative bacterium that appears in a rod-like 
shape, carrying a monotrichous flagella and several pili. P. aeruginosa does not derive 
its energy from fermentation of glucose. It thrives aerobically but can also grow under 
anaerobic conditions in the presence of nitrate. Thus, it is a facultative anaerobic 
nonfermenter. It is not very fastidious concerning its nutrition, making its identification 
in the laboratory uncomplicated. P. aeruginosa strains produce a variety of pigments 
such as pyrubin, pyomelanin, pyoverdin and pyocyanin. If pyoverdin and pyocyanin are 
produced the colonies shows a characteristical blue-green discolouration. The latin word 
aeruginosa is translated into „copper-rust“ or verdigris and describes its typical blue-
green color of laboratory cultures of the species (2). Wound infections due to P. 
aeruginosa can often be identified by its  „grapelike“ odor, which is produced by most 
strains (3). The organism can survive temperatures as high as 50°C and it can grow in 
distilled water. Water with a pH of 4.5 or lower does not allow the survival of P. 
aeruginosa (3).  
The pathogen causes a wide variety of infections in humans. Just as varied as the 
diseases P. aeruginosa causes, it produces and possesses a wide range of virulence 
factors, including endotoxins, exotoxins, type III secreted toxins, pili, flagella, 
proteases, phospolipases, iron-binding proteins, exopolysaccharides, the ability to 
produce biofilms and elaboration of pyocyanin (3).  
Most strains are able to produce an extracellular polysaccharide called alginate. It serves 
to protect the bacterium in different environmental conditions but also from the 
patient’s immune system. The production of these so-called biofilms plays a major role 
in the pathogenesis of cystic fibrosis (CF) patients. In CF-patients P. aeruginosa 
invades the thick mucus layers in the lungs. Despite limited oxygen levels in the mucus, 
the bacterium has the ability to produce an alginate (4), consequently shielding itself 
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from the body’s immune system (5) and it protects the pathogen from antibiotic 
treatment. 
P. aeruginosa is not the only species of the Pseudomonas genus known to cause 
infection in humans, albeit it is the most prominent bacterium. Pseudomonas spp. other 
than aeruginosa include Pseudomonas fluorescens, Pseudomonas putida, Pseudomonas 
cepacia, Pseudomonas stutzeri and Pseudomonas putrefaciens, just to name a few (6). 
They are occasionally isolated from human clinical specimens and can result in 
opportunistic infections (7, 8). However, non-aeruginosa Pseudomonas spp. are 
associated with a lower degree of virulence and infections and generally milder in 
course (7, 9, 10). 
 
 
1.1.2 Epidemiology 
 
P. aeruginosa is an opportunistic pathogen that primarily causes infection in 
immunocompromised hosts. It is a nosocomial pathogen that mostly infects hospitalized 
patients. It is also responsible for community-acquired infections in patients with severe 
underlying diseases such as cystic fibrosis, chronic obstructive pulmonary disease 
(COPD) or a debilitated immune system (11). Even though it rarely causes disease in 
healthy humans, it can lead to numerous diseases in such a setting, especially when the 
patient is exposed to moist environment.  
Bathing in contaminated swimming pools, hot tubs and whirlpools may lead to skin 
infections, referred to as folliculitis (12, 13). One of the leading causes for acute otitis 
externa, commonly known as „swimmer’s ear“ is P. aeruginosa (14). Patients who use 
particularly extended-wear contact lenses are at risk for sight-threatening infections due 
to P. aeruginosa. When infected they may suffer from ulcerative keratitis and 
endophaltmitis (15, 16). The bacterium can be found in contact lens solutions and it 
adheres to the contact lens surface more easily than other pathogens (17, 18). However, 
P. aeruginosa also plays a substantial role in the infection of puncture wounds and 
endocarditis linked to intravenous drug users (19). 
Data from the National Nosocomial Infections Surveillance (NNIS) System recorded in 
2003 has shown the distribution of gram-negative and gram-positive bacilli in hospitals 
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in the United States (US): P. aeruginosa is the second most common microorganism 
isolated in nosocomial pneumonia (18.1% of cases), accounts for 16.3% of cases of 
urinary tract infections, is the fifth most common cause of surgical site infection (9.5%) 
and has been isolated in blood stream infections in almost 4% of the cases (20). In 
hospitals, P.aeruginosa can be found in numerous reservoirs: hospital equipment such 
as cleaning solutions, mops, respiratory ventilators and surgical equipment. 
Furthermore, it has been isolated from sinks, drains, toilets and showers and is also 
reintroduced into the hospital’s environment through water used for flowers in patient’s 
rooms and spreads by contact of unsanitized hands (3). Nosocomial outbreaks due to 
unclean medical equipment have been described (21, 22). A severe outbreak of P. 
aeruginosa occurred during the winter of 2001-2002 in Norway involving 231 patients 
in 24 hospitals. Due to contaminated moist mouth-swabs and receipt of mechanical 
ventilation, 71 patients (31%) with severe underlying diseases died during 
hospitalization (22).  
Nosocomial infections are often associated with hospitalization in the intensive care unit 
(ICU), medical devices (e.g. mechanial ventilation, central venous catheter), previous 
antibiotic treatment and surgery (23).  
Outside of the hospital, P. aeruginosa lives ubiquitously in our environment: it can be 
found in soil, plants and water and also colonizes healthy animals and is part of the 
normal human flora or so-called microbiota. Up to 7% of healthy humans carry this 
bacterium in the throat, nasal mucosa, or on the skin. Transmission may occur through 
various modes, such as from patient to patient, from reservoir to patient and by 
colonization with subsequent autoinfection with the acquired strain (24).  
 
1.1.3 High-risk patients 
 
P. aeruginosa ist characterized as an opportunistic pathogen – a term that is used to 
describe organisms that may exist as part of the normal human flora and that are 
“capable of causing disease only when the host’s resistance is lowered” (25). P. 
aeruginosa is known to infect mostly immunocompromised patients. The state of 
impaired immune response may be either a consequence of an underlying disease and of 
the use of certain therapies that reduce or alter the patients’ immune system. Classically, 
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patients with neutropenic conditions were seen to be at high risk for P. aeruginosa 
bacteremia (26). Neutropenia is known as a condition with abnormally low neutrophile 
granulocytes (neutrophile count ≤500/µl). Neutrophile granulocytes play an important 
role in the host defense against pathogens. P. aeruginosa employs a wide array of 
virulence factors to invade the host and to evade the host’s immunological defense. Not 
only does it posses factors that inhibit phagocytosis by neutrophils (27), it also secretes 
leukocidin that kills neutrophils (28). Although P. aeruginosa infections were not 
frequently reported prior to 1960, cancer and immunosuppressive treatments were 
associated with an increased frequency of infection (29). In the late 1960s and the 1970s 
when effective antipseudomonal antbiotics were unavailable, P. aeruginosa was a 
common cause for infection in neutropenic patients with incidence rates reaching 55% 
(30). The incidence of P. aeruginosa changed after the introduction of carbenicillin and 
the pathogen spectrum in immunocompromised patients shifted from gram-negative to 
predominantly gram-positive microorganisms (31). Currently, the epidemiological 
situation seems to shift again, with several reports indicating a significant rise in gram-
negative infections in patients with underlying hematological malignancies (31-33), 
with high mortality rates reaching up to almost 40% for P. aeruginosa bacteremia (31). 
Trecarichi et al. (25) prospectively analyzed 575 bloodstream infections in patients with 
hematological malignancies and observed an increase in gram-negative infections with 
P. aeruginosa, Escherichia coli (E. Coli) and Klebsiella pneumoniae being the most 
prominent isolates.  
A number of studies have identified several patient groups at high risk for P. 
aeruginosa bacteremia due to an impaired immune system. Buhl et al. reviewed risk 
factors for acquisition of extensively drug-resistant (XDR) P. aeruginosa strains. 
Patients with a debilitated immune function, prior solid-organ transplantation and 
hematological malignancies were prone to infection or colonization (34).  
Although effective infection control measures and improved therapy procedures have 
led to a decrease in incidence of bacteremia due to P. aeruginosa in burn wound 
patients (35), P. aeruginosa is still the most frequent cause for burn wound infections in 
many centers (36). Pathophysiological knowledge may explain why this subgroup of 
patients is at risk for P. aeruginosa bacteremia. Pathogenesis of burn wound infection is 
based on an impaired immune system and the loss of the skin’s barrier function. Studies 
1. Introduction 
    5
have shown that patients with extensive burn wounds share compromised neutrophile 
functions and T-lymphocyte dysfunctions (37, 38). These mechanisms may predispose 
the patient for serious infection.  
 
1.1.4 Resistance 
 
P. aeruginosa is naturally (intrinsically) resistant to several antibiotics and it can also 
develop resistance towards multiple classes of antibacterial agents.  
P. aeruginosa is naturally resistant against the following antibiotics:  penicillin G, A, 
M, 1st and 2nd generation cephalosporins, some 3rd generation cephalosporins, 
ertapenem, kanamycin, tetracyclines, macrolides, cotrimoxazole and glcopeptides (39). 
Responsible for the pathogens intrinsic resistance are mechanisms such as expression of 
efflux pumps, low permeability of its outer membrane and naturally occurring AmpC β-
lactamases, only to name a few. Acquired resistance can result from mutation or from 
exogenous resistance determinants and can be achieved by a number of mechanisms, 
such as degrading enzymes (e.g. carbapenemases such as IMP and VIM (40)), reduced 
permeability and active efflux (41). 
While the prevalence of infections caused by P. aeruginosa has remained relatively 
stable, the prevalence of resistant isolates has increased in 2003 compared with 1998 
(42). Likewise, a national surveillance study of ICU patients identified an increase of 
multidrug-resistant (MDR) P. aeruginosa strains from 4% in 1993 to 14% in 2002 (43). 
In a survey of microbiological data from over 200 hospitals in the United States, the 
incidence of MDR among P. aeruginosa pneumonia isolates was found to be 22% and 
15% among bloodstream isolates (44). The emergence of MDR strains makes treatment 
of P. aeruginosa even more difficult.  
In order to create a uniformed and standardized characterization of resistance pattern, a 
joint-initiative by the ECDC and the CDC proposed a definition both for XDR and 
MDR P. aeruginosa strains (45). Beforehand, it is important to remember that the 17 
available antipseudomonal agents can be catalogued into the following 8 antimicrobial 
categories: antipseudomonal penicillins + β-lactamase inhibitors, monobactams, 
antipseudomonal cephalosporins, antipseudomonal carbapenems, antipseudomonal 
fluorochinolones, aminoglycosides, phosphoric acids and polymyxins. MDR P. 
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aeruginosa strains are resistant to at least one agent in at least three out of the eight 
categories. On the other hand, XDR P. aeruginosa strains show resistance to at least one 
agent in the minimum of six out of the eight categories.  
MDR P. aeruginosa strains show higher mortality rates when compared to multidrug-
susceptible strains (46, 47) which associated with increased patient morbidity (48). Risk 
factors associated with multidrug resistant P. aeruginosa strains include the following: 
Bedridden status, ICU stay, presence of invasive devices, prior use of certain antibiotics 
(including broad-spectrum cephalosporins, aminoglycosides, carbapenems, 
fluoroquinolones), Diabetes mellitus, malignant disease, undergoing surgery and HIV-
infection (48, 49). 
Buhl et al. reviewed the impact of therapeutic factors, patient-related factors, 
environmental factors and medical devices on risk for aquisition and colonization of 
XDR P. aeruginosa strains. Prior exposure to certain antibiotics such as 
fluorochinolones, carbapenem and amikacin were identified as a risk factor for 
acquisition for XDR P. aeruginosa, leading the authors to suggest that antibiotic 
therapy may lead to the selection of resistant strains. Furthermore, the use of medical 
devices (e.g. urinary catheter, mechanical ventilation, central venous catheter) were 
found to be independent risk factors for acquisition and colonization of XDR P. 
aeruginosa. Wet hospital reservoirs such as sinks were often suspected to be the source 
of exposition for patients (34).  
Available clinical data suggests that the emergence of MDR P. aeruginosa results in 
greater risk of death, longer duration of hospitalization (50) and an increase in surgery 
required for treatment (51), which consequently has a burdensome impact on healthcare 
costs (52).  
 
1.2 Bacteremia due to P. aeruginosa 
 
1.2.1 Epidemiology and clinical characteristics 
 
Incidence of bacteremia of P. aeruginosa has changed considerably over the past 
decades. Kerby et al. noted 91 cases of bacteremia due to P. aeruginosa in the world 
literature (53). Before 1950 only 1% of bacteremic cases were caused by this pathogen. 
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After 1950 the incidence increased to 7%-18%, causing mortality rates from 37%-77% 
(26). Numbers published in the 1970s have shown mortality rates of pseudomonas 
bloodstream infections surpassing 50% (54). A US nationwide prospective surveillance 
study (Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE)) 
analyzed 24.179 cases of BSI in 49 hospitals during a 7-year period (1995-2002) and 
concluded that 4% of the bloodstream infections were associated to P. aeruginosa, 
making it the 3rd leading cause of gram-negative infections (55). Several risk factors for 
BSI due to P. aeruginosa have been identified as neutropenia or other 
immunodeficiency (e.g. HIV and bone marrow transplants), severe burns, 
pancreatobiliary tract disease, urinary catheters or central venous lines, advanced age 
and recent hospitalization (56, 57). Typically, neutropenic and burn wound patients 
have been considered to be affected the most by Pseudomonas infection. However, most 
recent data has shown that the most frequent sources of bacteremia are the urinary and 
respiratory tract. This may be due to the use of indwelling urinary catheters and 
respiratory ventilators. Also, nosocomial outbrakes due to contaminated medical 
equipment used for ERCP (endoscopic retrograde cholangiopancreaticography) have 
been described (58, 59). 
BSI due to P. aeruginosa may present itself as benign transient bacteremia (8). 
Transient bacteremia may lead to fever; however it is typically asymptomatic and first 
and foremost describes bacteria circulating in the blood system without any pathogenic 
value.  Tachypnea, Tachykardia, mental disorientation and high fever may suggest 
development of sepsis. Common complications are respiratory failure due to pneumonia 
or acute respiratory distress syndrom (ARDS), development of DIC (disseminated 
vascular coagulation), renal failure and acute encephalopathia (60). Sepsis due to P. 
aeruginosa does not differ from sepsis due to other gram-negative bacteria in its clinical 
manifestation (28). Additional symptoms vary from site of infection. Certain patients 
with P. aeruginosa bacteremia develop a skin lesion known as Ecthyma gangraenosum 
(Eg). Eg is not pathognomic for P. aeruginosa, however, it is most frequently described 
in the setting of P. aeruginosa bacteremia in neutropenic patients. These patients 
present skin lesions as portal of entry. In its early stages the edema can be found around 
the lesion, progressing to a painful erythematous macula. Eventually, the macula turns 
into a necrotic ulcer. The lesion is a consequence of diffuse invasion of the 
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microorganism, particularly in the media and adventitia of the blood vessels. Eg is 
rarely occurs in mucosal areas and is usually found in the axilla, the gluteal and perianal 
region (28).   
 
1.2.2 Therapy of bloodstream infection 
 
Antibiotic therapy is the mainstay in the treatment of P. aeruginosa infections. The 
following antibiotics serve as therapy for P. aeruginosa infections (Tab.1): 
 
Table 1 - Antipseudomonal agents 
Class Agent/(Abbr.) 
Penicillins Piperacillin (PIP) 
Piperacillin/Tazobactam (PIP/TAZ) 
Ticarcillin-Clavulanate (not available in Germany) 
Cephalosporins Ceftazidime (CEF) 
Cefepime  
Monobactam Aztreonam (AZ) 
Fluorochinolones Ciprofloxacin (CIP) 
Levofloxacin  
Carbapenems Meropenem (MER) 
Doripenem  
Imipenem (IMP) 
Aminoglycosides Gentamicin (GM) 
Tobramycin 
Amikacin (AMK) 
Polymyxins Colistin (COL) 
Polymyxin B 
 
When P. aeruginosa bloodstream infection (BSI) is suspected, antimicrobial 
susceptibility testing should be initiated after drawing of blood cultures. Initial therapy 
is typically given as empiric therapy. Adequate empiric therapy should include agents 
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that cover P. aeruginosa, show the lowest local resistance rates within an institution, are 
in accordance to patient allergy history and hospital guidelines and have to be chosen 
depending on site of infection. It is also important to apply the antibiotic in a timely 
manner. A study has shown that a delay of more than 52 hours of administering the 
appropriate drug from the time the blood culture is drawn has at least doubled the 30-
day mortality (61). Thus, for successful therapy the interval between first positive blood 
culture and administration of the antibiotic needs to be kept as short as possible. 
Typically, a combination of an anitpseudomonal β-lactam (penicillin, cephalosporin or 
carbapenem) with either an aminoglycoside or a fluorochinolone is chosen as first-line 
empirical treatment (62, 63). Once laboratory results are available, antibiotic treatment 
shall be adjusted according to susceptibility results. The clinician also needs to take 
optimal dosing intervals into consideration. Due to their time-dependent activity, β-
lactam antibiotics should be applied frequently or by continuous infusion (64). Agents 
with concentration-dependent activity (e.g. aminoglycosides) shall be given as a single 
total daily dose (65). In addition to systemic antibiotic therapy, the primary site of 
infection needs to be addressed and infected catheters should be removed and 
obstructions and abscesses drained.  
Due to poor penetration into the central nervous system, lungs and abscesses, 
aminoglycosides are commonly avoided when infections involve these sites. 
Aminoglycosides are often combined with β-lactam antibiotics in order to enhance 
their antibacterial activity. β-lactam antibiotics work by inhibiting cell wall synthesis, 
consequently leading to open pores in the bacterial wall, allowing the aminoglycoside to 
penetrate more effectively (66). 
Fluorochinolones prevent the bacterial cell from duplicating by inhibiting certain 
enzymes (e.g. gyrase) and are the only antipseudomonal class of antibiotics that can be 
given orally (67). 
In the past, colistin and polymyxin B were typically agents of last resort due to fear of 
nephro- und neurotoxicity (68-70). However, it is suggested that colistin is effective 
against multidrug resistant bacteria (71, 72) and therefore may be administered when 
choices are limited. Moreover, nephrotoxicity is often reversible and neurotoxicity 
occurs rarely (73). 
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1.2.3 Combination versus monotherapy 
 
There has been controversial debate on whether combination therapy is superior to 
monotherapy. Around 1972, the outcome for neutropenic patients presenting with P. 
aeruginosa bacteremia was dismal due to scarceness of antipseudomonal agents. At that 
time, the common antipseudomonal agents were gentamicin and polymyxins (74). 
During that time two studies revealed that therapy with carbenicillin improved the 
outcome in neutropenic patients with P. aeruginosa bacteremia (74, 75). Several 
retrospective analyses suggested that a combination of synergistic antibacterial agents 
for gram-negative pathogens would lead to better outcomes in neutropenic patients (76, 
77). Thus, combination therapy was set as the standard approach for the treatment of P. 
aeruginosa infections. At a time when ceftazidime was arguably the best 
antipseudomonal agent, a study conducted in 1986 showed successful treatment with 
ceftazidime monotherapy (78). In the following years several studies addressed this 
issue and compared monotherapy to combination therapy in P. aeruginosa patients (79-
81). However, no clear conclusion could be drawn from the wide range of studies 
conducted in the past 20-30 years due to the paucity of well-controlled studies using 
clinically important end points. Experts today favor the use of combination therapy for 
P. aeruginosa. The IDSA (Infectious Diseases Society of America) concluded in 2002 
that empirical monotherapy in high-risk patients suffering from P. aeruginosa 
bacteremia present the same efficiency as empirical combination therapy (82). It is also 
important to acknowledge that the drawbacks of combination therapy are linked to 
higher costs and an increase of toxicity. For example, a systematic review and meta-
analysis of randomized trials found nephrotoxicity to be more common in combination 
therapy (83). 
 
1.2.4 Prognosis of bloodstream infections due to P. aeruginosa 
 
Prognosis for P. aeruginosa BSI infections remains poor despite advances in therapy 
over the past decades. Wisplinghoff et al. analyzed 24,179 cases of nosocomial BSI in 
US hospitals. The authors found crude mortality rates of 27.6% for non-ICU patients 
and 47% for ICU patients with BSI due to P. aeruginosa (55). A prospective study 
conducted in 2001-2002 compared hospital mortality of bloodstream infections due to 
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Staphyloccocus aureus and P. aeruginosa. They found mortality with P. aeruginosa to 
be significantly higher in contrast to mortality due to Methicillin-sensitive 
Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus 
(MRSA) (30.6%, 16.2%, 13.5% respectively) (84).  
Investigation has shown that several risk factors are associated with higher mortality in 
patients with P. aeruginosa bacteremia. In a study where 133 patients with P. 
aeruginosa bacteremia were examined, four variables influencing outcome were 
defined as development of septic shock, granulocyte count under 500/mm3, 
inappropriate antibiotic therapy and development of septic metastasis (85). Furthermore, 
drug resistance also negatively influences survival (86, 87). A study of 100 episodes of 
P. aeruginosa demonstrated that underlying host disease is directly related to the 
patient’s survival (88). 
 
1.3 Other types of P. aeruginosa infections 
 
1.3.1 Respiratory tract infections 
 
P. aeruginosa has been reported to cause infections in various sites of the body. 
However, its role in lung diseases is of particular importance. 
P. aeruginosa is a common pathogen causing hospital-acquired pneumonia (HAP), 
where the incidence has almost doubled in the years from 1975 to 2003, from 9.6% to 
18.1% respectively (20). Mode of transmission is through aspiration of endogenous oral 
flora, via aspiration of the pathogens through contaminated ventilator tubing and other 
medical devices or through hematogenous dissemination (89, 90). 
It is also one of the most common bacteria causing ventilator-associated pneumonia 
(VAP) (91), with attributal mortality rates as high as 13% (92). Per definition VAP is a 
pneumonia that develops 48 to 72 hours after intubation, where the patient’s 
oropharyngeal tract is in direct contact with respiratory devices.  
Eventhough community-acquired pneumonia (CAP) due to P. aeruginosa in otherwise 
healthy patients is rare, P. aeruginosa infection in this setting is not neglectable due to 
high crude mortality rates reaching up to 61.1% (93) . Nonetheless, P. aeruginosa CAP 
does occur more frequently in patients with underlying risk factors such as chronic 
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obstructive pulmonary lung diseases (COPD), HIV infection and structural lung 
diseases such as cystic fibrosis (94, 95). 
P. aeruginosa is also the key bacterial agent of cystic fibrosis (96). Most patients get 
chronically infected with P. aeruginosa strains during childhood. The Cystic Fibrosis 
Foundation’s 2015 Patient Registry Annual Data Report found prevalence of patients 
cultured positive for P. aeruginosa to have declined over the past ten years. In 1995 
50.7% of CF-patients showed positive blood cultures for P. aeruginosa compared to a 
30.4% in the year of 2015 (97).  
Pneumonia due to P. aeruginosa is clinically not clearly distinguishable from other 
pathogens and infected patients typically present with fever and purulent cough (23). 
Generally, diagnosis of pneumonia is based on radiological findings, identification of 
clinical symptoms and results from microbiological pathogen testing. P. aeruginosa 
pneumonia does not display a specific feature in chest radiology (98). In order to obtain 
cultures from the lung it is suggested to perform invasive procedures such as 
bronchoalveolar lavage (23). P. aeruginosa is rarely isolated in blood cultures from 
pneumonia patients (98). 
The American Thoracic Society and the Infectious Diseases Society of America 
advocates the use of combination therapy with either a β-lactam or carbapenem in 
combination with either a fluorochinolone oder an aminoglycoside (99). Parenteral 
monotherapy with an aminoglycoside is not recommended because these agents 
perform poorly in the acidic environment of the lung. (23). Inhaled antibiotics may be 
useful to treat resistant strains. Despite the fear of toxic side effects, pneumonia due to 
MDR P. aeruginosa has been successfully treated with aerosolized colistin (99). 
 
1.3.2 Burn wound infections 
 
In the 1960s and 70s P. aeruginosa posed one of the most significant threats in burn 
wound infections. At that time and in contrast to today, as many as 10% of burn wound 
patients suffered from P. aeruginosa bacteremia (100). Today, the occurrence of P. 
aeruginosa in burn wound patients has decreased. In a large study 1400 burn wound 
patients were examined and showed that roughly 1% of the patients suffered from P. 
aerugnosa sepsis (101).  However, P. aeruginosa remains the most frequent 
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migroorganism isolated from burn wounds, following Acinobacter and Escherichia coli 
(102). 
Typically, 48 hours after thermal injury, gram-positive pathogens like staphylococci 
that have survived colonize the burn wound. Subsequently other gram-negative 
pathogens and yeast infect the avascularized necrotic burn eschar (103, 104). After such 
invasion, microorganisms can proliferate in necrotic tissue and invade the blood system, 
leading to secondary bacteremia. 
Diagnosis of burn wound infection is achieved through examination of clinical signs 
and of burn wound swabs in the laboratory. In order to distinguish between human 
bacterial flora and infection, a colony count of ≥105 organisms per gram tissue is 
indicative of burn wound infection. Urinary samples, respiratory and blood cultures may 
also be used for diagnosis (105). 
Treatment of P. aeruginosa burn wound infections includes topical and systemic 
application of antimicrobial agents and aggressive surgical debridement of the necrotic 
tissue. Topical agents such as silver nitrate have strong bacteriostatic activity against 
gram-negative bacteria such as P. aeruginosa (106).  
Although incidence rates for P. aeruginosa in burn wound patients have considerably 
decreased, mortality remains alarmingly high, reaching rates up to 77% in some burn 
centers (100, 102).  
 
1.3.3 Ear infections 
 
P. aeruginosa is known to cause acute otitis externa (“swimmer’s ear”) and the most 
frequent pathogen in malignant otitis externa (26). 
Swimmer’s ear typically occurs in children and under moist or humid conditions. Pain, 
itchiness, mucoid discharge and hearing loss are typical clinical signs (107). Therapy 
consists of local application of solutions containing an aminoglycoside (23).  
Malignant otitis externa is a more dreaded infection, initially affecting the ear canal and 
cartilage of the ear (23). Subsequently, the infection proceeds to the soft tissue of the 
retromandibular area and cranial nerves. Nerve palsy, osteomyelitis, brain abscesses and 
dural vein thrombosis are typical complications (28). 
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Diagnosis consists of isolation of the pathogen from ear exsudate and a nuclear imaging 
technique with technetium 99 of the bone. Treatment consists mainly of antibiotic 
treatment; nonetheless débridement or abscess drainage may be required. 
Antipseudomonal agents such as penicillins, aminoglycosides or cephalosporins are 
applied intravenously for a duration of 6 to 8 weeks. Alternatively, ciprofloxacin can be 
applied orally (108).  
 
1.3.4 Urinary tract infections 
 
Urinary tract infections (UTI) caused by P. aeruginosa are generally hospital-acquired. 
P. aeruginosa accounts for approximately 7% of UTI in this setting and ranks third in 
causes for hospital-acquired UTI, following Escherichia Coli and Enterococci (109).  
These infections typically occur in male patients, after longer stays in other hospitals 
and are associated with prior penicillin use and indwelling urinary catheters (110).  
Typical clinical features for UTI such as dysuria, hematuria, fever, suprapubic and flank 
pain are not any different when caused by P. aeruginosa.  
During the course of treatment, foreign bodies (e.g. indwelling catheters, stents and 
stones) should be removed and an antibiotic such as ciprofloxacin (23) for systemic 
treatment should be applied.  
Due to P. aeruginosa’s propensity to form a biofilm on the catheters’ surface, UTI due 
to P. aeruginosa is often associated with persistent and recurrent episodes (111).  
  
1.3.5 Infections of the central nervous system 
 
Primary infections of the central nervous system (CNS) due to P. aeruginosa are 
uncommon. This pathogen is mostly involved in secondary infections – infections that 
occur in connection to head trauma and in the course of surgical procedures (112). 
Typical clinical syndromes are meningitis, brain abscesses, subdural and epidural 
infections (23).  
The profile of the cerebrospinal fluid of P. aeruginosa is similar to that of other 
bacterial meningitis. Symptoms of this entity include neck stiffness, fever and altered 
mental status and are not any different to those of other gram-negative pathogens (113). 
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Once the pathogen has been identified, an intravenous antimicrobial therapy with either 
cefepim or ceftazidim is suggested. Alternatively, aztreonam, ciprofloxacin or 
meropenem can be applied (114). It is occasionally necessary to install an antimicrobial 
agent by the intraventricular route (114) in patients with difficult or persistent 
infections. In addition, it is required to drain abscesses and empyemas and to remove 
foreign bodies such as ventriculostomy tubes. 
 
1.4 Objectives of the thesis 
 
P. aeruginosa is one of the most common causes for nosocomial infections, and despite 
advances in treatment options, mortality for BSI due to P. aeruginosa remains high 
(115). P. aeruginosa seldom causes infections in otherwise healthy patients, however, 
immunocompromised patients, patients carrying medical devices and ICU patients are 
at high risk for BSI due to P. aeruginosa (116-118).  
P. aeruginosa employs a wide array of virulence factors, which may in part explain the 
deleterious impact on survival. In addition to its high intrinsic resistance towards many 
antibiotics, P. aeruginosa has the capacity to rapidly develop resistance during 
antimicrobial therapy (23). Rates of antipseudomonal resistance continue to rise 
worldwide (20, 119), limiting the choices of effective therapeutic options.  
In order to adequately treat patients with suspected BSI due to P. aeruginosa, the 
physician needs to determine who is at risk for infection with this pathogen. To date, 
experts have not reached consensus on how to adequately treat BSI due to P. 
aeruginosa (120-122). In addition, the clinician must find a balance between choosing 
the best treatment options for improved outcome but at the same time limiting the 
spread and increase in resistance and drug toxicity. 
In this regard, our study aimed to examine: 
1. All-cause hospital mortality among patients with BSI due to P. aeruginosa and risk 
factors associated with increased mortality, 
2. Impact of appropriate and inappropriate antipseudomonal therapy on mortality, 
3. Whether antipseudomonal combination therapy is superior to monotherapy, 
4. Impact of carbapenem resistance on mortality in P. aeruginosa BSI. 
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2. Material & Methods 
 
2.1 Study design 
 
We conducted a study as part of an international, multicenter, retrospective, cohort-
study in 19 hospitals in 10 countries (Tab. 2) (project leaders: Dr. Dafna Yahav and 
Prof. Leonard Leobovici in Tel-Aviv/Israel). Aim of the international study was to 
compare treatment options for P. aeruginosa bacteremia. A preliminary summary of the 
study has been presented at the European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID) in April 2018 in Seville, Spain. We obtained written 
permission to use the data for our own analysis. 
The institutional review board in Germany approved the study. Informed consent of the 
patients was not required due to the retrospective nature of the study. Patient data was 
extracted in a pseudonymised form.  
We reviewed medical records and microbiological laboratory results of patients 
hospitalized during the 1st of January 2009 until the 31st of October 2015. We included 
patients aged ≥ 18 years old and who had a positive blood culture for P. aeruginosa. 
Polymicrobial infections and recurrent episodes in the same patient were excluded from 
the study. 
 
Table 2 - List of participants of the international, multicenter study 
Country Centre 
Australia The University of Queensland, Centre for 
Clincial Research, Brisbane 
England North Bristol NHS Trust, Southmead 
Hospital 
France Centre Hospitalier Regional Universitaire 
de Nancy, Nancy 
Germany University Hospital Tübingen, Tübingen 
Greece University Hospital Heraklion, Iraklio 
Israel HaEmek Medical Center, Afula 
Rambam Health Care Campus, Haifa 
Sourasky Medical Center, Tel Aviv 
Soroka Medical Center, Beersheba 
Italy Bolzano Central Hospital, Bolzano 
2. Material & Methods 
    17 
Slovenia University Medical Centre, Ljubljana 
Spain Hospitales Universitario Virgen 
Macarena, Sevilla 
Hospital De Sant Pau, Barcelona 
Hospitales Universitario Virgen del 
Rocio, Sevilla 
Hospital Universitario Son Espases, 
Palma de Mallorca 
Hospital Universitario Reina Sofia, 
Cordoba 
Hospital Universitario Marqués de 
Valdecilla, Santander 
Hospital Universitario y Politecnico de La 
Fe, Valencia 
Sweden Karolinska University Hospital, Solna 
 
2.2 Setting 
 
University Hospital Tübingen is a 1,500-bed hospital that provides specialized and 
general treatment in all medical specialties including medical, surgical and intensive 
care. It serves both as teaching hospital of Tübingen University and District Hospital for 
the Town and the Administrative District of Tübingen.  
2.3 Data collection 
 
Demographic, clinical and microbiological data were collected from electronic medical 
and archived records for all patients. Patients were identified by positive blood culture 
for P. aeruginosa in microbiological laboratory records. Microbiological data was 
extracted from SAP-sytem, Lauris-system and in part from swisslab-system. Clinical 
and demographical data were collected from SAP-system and Lauris-System. The data 
was then entered into an Excel-table. When specific data could not be obtained from the 
electronic records, the cell in the Excel-table was left blank. Variables were encoded as 
binary variables (e.g. no=0, yes=1), except the variables ‘age’, ‘date of hospitalization’ 
and ‘date of death’. 
Following variables were collected for each patient:  
- Age 
- Gender 
- Date of hospital admission 
- Department of hospitalization 
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• Medical 
• Surgical  
• ICU 
- Place of acquisition (of infection) 
• Nosocomial 
• Community-acquired 
- Previous hospitalization in the previous 90 days 
- Medical devices upon admission: 
• Endotracheal tube 
• Central venous line 
• Nasogastric tube 
• Prosthesis 
- Predisposing conditions at admission: 
• Neutropenia 
• Organ transplant 
• Chemotherapy 
• Corticosteroid use 
• Surgery 
- Microbiological susceptibility data: 
• Gentamicin (GM) 
•  Piperacillin (PIP) 
• Piperacillin/tazobactam (PIP/TAZ) 
• Ceftazidime (CEF) 
• Ciprofloxacin (CIP) 
• Meropenem (MER), 
• Fosfomycin (FOS) 
• Aztreonam (AZ) 
• Colistin (COL) 
• Amikacin (AMK)  
• Imipienem (IMP) 
- Antipseudomonal agents for empirical therapy 
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2.4 Definitions 
 
Table 3 - Variable definitions 
Variable  Definition 
Pseudomonas aeruginosa bacteremia Isolation of the pathogen in a blood 
culture. 
Department of hospitalization Clinical department where blood for the 
initial blood cultures was taken. ‚ICU’ 
included the ICU of surgical and medical 
department. 
Nosocomial infection Onset of bacteremia ≥48 hours after 
hospitalization. 
Community-acquired infection Cases that were not marked as ‚nosocomial 
infection’ were considered community-
acquired. 
Source of bacteremia Sources were determined by the physician 
responsible for data extraction based on the 
information from the medical records. 
When a localized infection could not be 
determined, the source of bacteremia was 
categorized as ‚unknown’. In many cases 
the treating physician did not document the 
source. Bacteremia in the presence of any 
central line and in the absence of another 
source where categorized as ‚line-
associated’. 
Neutropenia Absolute neutrophile count below 500 
cells/mm3 
Organ transplant Included solid organ transplant and 
autologous/allogeinic hematopoetic stem 
cell transplant in the previous 30 days. 
Chemotherapy Any type of cytotoxic therapy in the 
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previous 30 days. 
Corticosteroid use Administration of ≥ 10 mg/d prednisone in 
the previous 30 days.  
Surgery Any type of surgery - except percutaneous 
procedures and angiography - in the 
previous 30 days. 
Previous hospitalization Hospitalization in the previous 90 days as 
an in-patient before the current 
hospitalization. 
Multidrug resistance Resistance to two or more 
antipseudomonal drugs. 
Carbapenem resistance P. aeruginosa was considered as 
carbapenem resistant if the strain was 
resistant to either imipenem or meropenem 
Empirical therapy Administration of antipseudomonal 
treatment within 24h of first positive blood 
culture. 
Antipseudomonal monotherapy Administration of one of the following 
agents: gentamicin, amikacin, ceftazidim, 
ciprofloxacin, levofloxacin, ofloxacin, 
piperacillin, piperacillin/tazobactam, 
imipenem, meropenem, doripenem, 
aztreonam, cefepim, tobramycin and 
fosfomycin. 
Appropriate monotherapy At least one prescribed antibiotic had to 
match the in vitro susceptibility of the 
respective P. aeruginosa isolate. 
Antipseudomonal combination therapy Administration of one of the following 
combination options:  
(I) piperacillin, piperacillin/tazobactam, 
meropenem, ceftazidim, doripenem, 
colistin, cefepim was combined with either 
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a fluorchinolone (levofloxacin, 
ciprofloxacin) or an aminoglycoside 
(amikacin, gentamicin, tobramycin), 
(II) meropenem and 
piperacillin/tazobactam, 
(III) cefepim and meropenem, 
(IV) colistin and piperacillin/tazobactam, 
(V) colistin and cefepim, 
(VI) meropenem and ceftazidim, 
(VII) colistin and doripenem. 
Appropriate combination therapy Both antipseudomonal agents had to match 
in vitro susceptibility of the respective P. 
aeruginosa isolate. 
Inappropriate therapy Administration of an antipseudomonal 
agent to which the pathogen was tested 
resistant in vitro. 
 
2.5 Microbiological testing 
 
Blood was obtained from every patient and inoculated into a two-bottle set. Although it 
is recommended to follow standard protocol and collect blood from at least two 
locations (123, 124), in practice the microbiological laboratory may also receive one 
blood culture set. 
In University Hospital of Tübingen blood cultures are tested using BD BACTEC™ 
Instrumented Blood Culture Systems (Becton, Dickinson and Company, New Jersey, 
USA). Gram staining and subculture was performed. Subsequently, microorganisms 
were examined according to routine bacteriological procedures. Species were identified 
by the means of a linear MALDI-TOF mass spectrometer (Shimadzu, Kyoto, Japan). 
Antimicrobial resistance was routinely tested by microbroth method on a Vitek 2 system 
(bioMérieux, Marcy l'Étoile, France). The following antimicrobials were tested in our 
center: gentamicin, amikacin, piperacillin, piperacillin/tazobactam, ceftazidim, 
ciprofloxacin, meropenem, fosfomycin, colistin, imipenem and aminoglycoside. We 
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considered intermediate suscpeptibility tested isolates to be resistant. Susceptibility was 
interpreted following EUCAST (European Committee on Antimicrobial Susceptibility 
Testing) guidelines with the exception of colistin to which susceptibility was evaluated 
according to CLSI (Clinical and Laboratory Standards Institute) recommendations (125, 
126). 
In the microbiological institute in Tübingen blood culture bottles are examined during 
the week 7.30 a.m. to 5.30 p.m. and on weekends 7.30 a.m. to 3 p.m. Laboratory results 
are transferred into the hospital computer system (SAP-system), which is accessible to 
the physician. However, the laboratory also provides on-call service for the physician. 
 
2.6 Statistical analysis 
 
Data were analyzed using STATA 14.2 for Windows (StataCorp, College Station, TX, 
USA) Software. Descriptive analysis of the study population is presented as proportion 
for categorical variables and as mean with standard deviation for continuous variables. 
Factors associated with risk of mortality among patients admitted to the hospital with P. 
aeruginosa infection were assessed using survival Cox proportional hazard model, 
wherein the total person-time at risk was calculated as the total days under surveillance 
(time from the day patient tested positive for P. aeruginosa in blood culture until 
discharge/death). Factors identified in the univariate analysis at the significance level of 
0.30 and clinically relevant variables were considered for inclusion in the full 
multivariate models. Multivariate analysis was performed using backward stepwise 
method. The risk is presented as hazard ratio (HR) with 95% confidence interval (CI). 
Kaplan-Meier estimates of median survival time were calculated and compared for 
patients who received appropriate and inappropriate empirical and definitive therapy. 
Significance was assumed at a 5% level.  
Survival analysis is commonly used for statistical analysis of clinical trials. In survival 
analysis, time-to-event is recorded, whereas the event (outcome) may be death, time to 
hospitalization, relapse, recovery etc. This method of analysis includes patients who 
reach the chosen outcome and those who fail to complete the trial (censored data). This 
allows us to take into consideration as much information as possible, in order to 
optimize the power or validity of the study. Data from the survival analysis may then be 
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depicted in Kaplan-Meier curves. There are several models that can be used for time-to-
event analysis, such as log-rank test and Cox proportional hazard model (127). Cox 
proportional hazard model is a survival regression model that identifies differences in 
survival with respect to treatment and prognostic factors. This model gives an estimate 
of the hazard ratio (128). Hazard ratio is seen as a type of relative risk that compares 
survival times between two groups of patients (129). 
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3. Results 
3.1 Study population 
 
A total of 104 patients presenting P. aeruginosa bacteremia during a hospitalization 
from the 1st of January 2009 until the 31st of October 2015 were included in the study. 
The mean age was 63.7 ± 14 (standard deviation). In our cohort 68 patients were male 
and 36 were female.  Most frequent department of hospitalization was the medical 
department (67 patients, 64.4%), followed by the ICU (29 patients, 27.9%) and the 
surgical department (8 patients, 7.7%). A total of 74 (71.2%) infections were 
nosocomially acquired, whereas the remainder cases were considered as community-
acquired (28.8%). The presumed sources of bacteremia were pulmonary (21 patients, 
20.6%), urinary (11 patients, 10.8%), line-associated (10 patients, 9.8%) and in 45 
(58.5%) cases the source of infection was unknown. ‘Unknown’ source of infection was 
determined during data extraction when the treating physician did not document the 
source or could not determine a source of infection.  In our cohort 20 patients (19.2%) 
were neutropenic, 13 patients (12.5%) had undergone an organ transplant and 19 
patients (18.3%) had surgery in the previous 30 days. Of 101 patients, 19 patients 
(18.8%) had received corticosteroid therapy in the previous 30 days and of 102 patients, 
19 patients (18.6%) had received chemotherapy in the previous 30 days. Of 103 patients 
67 patients (64.4%) had been hospitalized in the previous 90 days. In the last three cases 
and in further cases below, data could not be obtained due to missing medical records, 
thus reducing the sample size. Furthermore, we recorded medical devices that patients 
were carrying upon admission. 10 (9.6%) patients had an endotracheal tube, 36 (34.6) 
patients had a central venous line (CVL), 6 (5.8%) had a nasogastric tube, 15 (14.4%) 
had an indwelling urinary catheter and 32 (31.1%) had a prosthesis. Clinical and 
epidemiological characteristics are shown in Tab. 4. 
Empiral therapy was analysed in 92 patients; in 12 patients data was incomplete. Of 71 
patients who received appropriate empirical therapy, 47 patients (51.1%) received 
appropriate empirical monotherapy and 24 patients (26.1%) received appropriate 
empirical combination therapy. Of the 21 patients who received inappropriate empirical 
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therapy, 13 patients (14.1%) received monotherapy and 8 patients (8.7%) received 
combination therapy.  
 
Table 4 - Clinical and epidemiological characteristics of the study population 
Characteristics (n=104) Patients 
Age, years (mean±SD) 63.7±14 
Sex 
Male 
Female 
 
68 (65.4) 
36 (34.6) 
Department of hospitalization 
Surgical 
Medical 
ICU 
 
8 (7.7) 
67(64.4) 
29 (27.9) 
Place of acquisition 
Community-acquired 
Nosocomial 
 
30 (28.8) 
74 (71.2) 
Source of bacteremia (n=101)* 
Unknown 
Line-associated 
Pulmonary 
Urinary 
 
50 (49.5) 
10 (9.9) 
27 (26.7) 
14 (13.9) 
Predisposing condition 
Neutropenia 
Organ transplant 
Chemotherapy within previous 30 days (n=102)* 
Corticosteroid use within previous 30 days (n=101)* 
Surgery within previous 30 days 
Hospitalization within previous 90 days (n=103)* 
 
20 (19.2) 
13 (12.5) 
19 (18.6) 
19 (18.8) 
19 (18.3) 
67 (64.4) 
Invasiv devices upon admission 
Endotracheal device 
Central venous line 
 
10 (9.6) 
36 (34.6) 
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Nasogastric tube 
Urinary catheter 
Any prosthesis (n=103)* 
6 (5.8) 
15 (14.4) 
32 (31.1) 
Treatment 
Empirical therapy (n=92)* 
Appropriate empirical therapy 
Appropriate empirical monotherapy 
Appropriate empirical combination therapy 
Inappropriate empirical therapy 
Inappropriate empirical monotherapy 
Inappropriate empirical combination therapy 
 
 
71 (77.2) 
47 (51.1) 
24 (26.1) 
21 (22.8) 
13 (14.1) 
8 (8.7) 
SD=standard deviation. ICU=intensive care unit. CVL=central venous line. 
The coloumn ‚patients’ is expressed in total numbers (with percentages in brackets), while ‚age’ 
as the only continuous variable is presented as mean age (with standard deviation in brackets). 
*With regard to certain charateristics, some data of the sample size n=104 was either missing in 
the medical records or was not of relevance for our study and thus the sample size was smaller 
(smaller than 104) in these cases. 
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3.2 Microbiological characteristics 
 
Susceptibility patterns of the P. aeruginosa blood isolates are shown in Fig. 1.  
Of 103 isolates that were tested for the susceptibility of gentamcin, 21 (20.4%) were 
resistant to gentamicin. Of the 31 isolates tested for amikacin, 17 (54.8%) were 
resistant. Of 104 isolates tested for piperacillin, 33 (31.7%). Of 104 isolates tested for 
piperacillin/tazobactam, 31 (29.8%) were resistant. Of 103 isolates tested for 
ceftazidim, 27 (26.2%) were resistant. Of 104 isolates tested for ciprofloxacin, 31 
(29.8%) were resistant. Of 102 isolates tested for meropenem, 32 (31.4%) were 
resistant. Of 27 isolates tested for fosfomycin, 26 (96.3%) were resistant. Of 30 isolates 
tested for colistin, 2 (6.7%) were resistant. Of 4 isolates tested for imipenem, 2 (50%) 
were resistant. 
 
Figure  1 - Percentage distribution of the susceptibility profile of P. aeruginosa 
BSI 
 
Resistance rates for gentamicin, amikacin, piperacillin, piperacillin/tazobactam, 
ceftazidim, ciprofloxacin, meropenem, fosfomycin, colistin and imipenem were 20.4%, 
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54.8%, 31.7%, 29.8%, 26.2%, 29.8%, 31.4%, 96.3%, 6.7% and 50%, respectively. The 
x-axis shows the antibiotics and their respective sample sizes.  
The y-axis shows the percentage of the tested isolates shown as susceptible (black) and 
resistant (grey). 
Numbers in brackets describe the amount of P. aeruginosa strains tested. 
 
3.3 Univariate analysis of risk factors associated with all-cause hospital mortality 
 
Among all patients, the overall mortality was 37.5% (39/104). Among neutropenic 
patients all-cause mortality was 60% (12/20) and among non-neutropenic patients 32% 
(27/84). All-cause hospital mortality among patients with pulmonary-associated 
infections was 47% (10/21) and if the source of infection was unknown, the all-cause 
hospital mortality was 51% (23/45). In contrast, patients with line-associated infections 
had a comparatively lower all-cause hospital mortality of 10% (1/10). Risk factors for 
all-cause hospital mortality are presented in Tab. 5. According to univariate analysis, 
mortality was associated with chemotherapy (adjusted HR 2.12 [95% CI 1-4.5]; 
p=0.04), neutropenia (adjusted HR 2.54 [95% CI 1.25-5.18], p=0.01), an unknown 
source of infection (adjusted HR 2.45 [95% CI 1.28-4.69]; p=0.006), multi-drug 
resistant strains (adjusted HR 3.05 [95% CI 1.53-6.08]; p=0.001), inappropriate 
empirical therapy (adjusted HR 2.24 [95% CI 1.12-4.49]; p=0.02) and inappropriate 
empirical monotherapy (adjusted HR 3.13 [95% CI 1.16-8.44]; p=0.02). 
 
Table 5 - Risk factors for all-cause hospital mortality in P. aeruginosa BSI based on 
univariate analysis 
Variable Survivors, 
(%) 
Non- 
survivors, 
(%) 
HR (95% CI) p-valuea 
Age (n=104) 
Age ≤55 years 
Age ≥75 years 
 
15 (55.6) 
18 (90) 
 
12 (44.4) 
2 (10) 
 
1.0 (reference) 
0.24 (0.05-1.07) 
 
 
0.06 
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Variabel Survivors, 
(%)b 
Non-
survivors, 
(%)b 
HR (95% CI) p-valuea 
Sex (n=104) 
Male 
Female 
 
44 (64.7) 
21 (58.3) 
 
24 (35.3) 
15 (41.7) 
 
1.0 (reference) 
1.25 (0.66-2.40) 
 
 
0.48 
Devices upon admission 
(n=104) 
Endotracheal 
CVL 
Nasogastric tube 
Urinary catheter 
Any prosthesis 
 
 
7 (70) 
23 (63.9) 
4 (66.6) 
12 (80) 
25 (78.1) 
 
 
3 (30) 
13 (36.1) 
2 (33.3) 
3 (20) 
7 (21.9) 
 
 
1.33 (0.40-4.40) 
1.02 (0.52-1.99) 
1.55 (0.36-6.55) 
0.58 (0.18-1.91) 
0.61 (0.26-1.40) 
 
 
0.64 
0.94 
0.55 
0.38 
0.25 
Predisposing condition 
Chemotherapy in the last 
30 days (n=102) 
Corticosteroid use in the 
last 30 days (n=101) 
Surgery in the last 30 days 
(n=104) 
Non-neutropenic 
Neutropenia (n=104) 
Organ transplant (n=104) 
 
9 (47.4) 
 
10 (52.6) 
 
14 (73.7) 
 
57 (68) 
8 (40) 
7 (53.8) 
 
10 (52.6) 
 
9 (47.4) 
 
5 (26.3) 
 
27 (32) 
12 (60) 
6 (46.2) 
 
2.12 81-4.5) 
 
1.83 (0.84-3.97) 
 
0.59 (0.23-1.53) 
 
1.0 (reference) 
2.54 (1.25-5.18) 
1.05 (0.44-2.53) 
 
0.04 
 
0.12 
 
0.28 
 
 
0.01 
0.9 
Source of bacteremia (n=101) 
Urinary 
Unknown 
Line-associated 
Pulmonary 
 
11 (78.6) 
23 (46.0) 
 9 (90) 
12(44.5) 
 
3 (21.4) 
27 (54.0) 
1 (10) 
15 (55.5) 
 
1.0 (reference) 
2.45 (1.28-4.69) 
0.20 (0.03-1.48) 
1.05 (0.51-2.18) 
 
 
0.006 
0.11 
Place of acquisition (n=104) 
Community-acquired 
infection 
Nosocomial infection 
 
19 (29.2) 
 
46 (70.8) 
 
11 (28.2) 
 
28 (71.8) 
 
1.0 (reference) 
 
0.68 (0.33-1.40) 
 
 
 
0.3 
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Variabel Survivors, 
(%)b 
Non-
survivors, 
(%)b 
HR (95% CI) p-
valuea 
Antibiotic susceptibility 
Gentamicin 
Susceptible 
Resistant 
Amikacin 
Susceptible 
Resistant 
Piperacillin 
Susceptible 
Resistant 
Piperacillin /Tazobactam  
Susceptible 
Resistant 
Ceftazidim 
Susceptible 
Resistant 
Ciprofloxacin 
Susceptible 
Resistant 
Meropenem 
Susceptible 
Resistant 
Fosfomycin 
Susceptible 
Resistant 
 
 
58 (70) 
6 (28.6) 
 
6 (42.9) 
4 (23.5) 
 
52 (73) 
13 (39.4) 
 
55 (77.5) 
10 (32.3) 
 
53 (69.7) 
11 (40.7) 
 
53 (72.6) 
12 (38.7) 
 
51 (72.8) 
12 (37.5) 
 
0 (-) 
7 (27) 
 
 
24 (30) 
15 (71.4) 
 
8 (57.1) 
13 (76.5) 
 
19 (26) 
20 (60.6) 
 
18 (22.5) 
21 (67.7) 
 
23 (30.3) 
16 (59.3) 
 
20 (27.4) 
19 (61.3) 
 
19 (27.2) 
20 (62.5) 
 
1 (100) 
19 (73) 
 
 
1.0 (reference) 
2.34 (1.22-4.46) 
 
1.0 (reference) 
1.48 (0.60-3.64) 
 
1.0 (reference) 
2.40 (1.28-4.51) 
 
1.0 (reference) 
2.78 (1.48-5.23) 
 
1.0 (reference) 
1.88 (1.0-3.56) 
 
1.0 (reference) 
1.98 (1.05-3.72) 
 
1.0 (reference) 
2.35 (1.25-4.42) 
 
- 
- 
 
 
 
0.01 
 
 
0.38 
 
 
0.006 
 
 
0.001 
 
 
0.05 
 
 
0.03 
 
 
0.008 
 
- 
- 
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Variabel Survivors, 
(%)b 
Non-
survivors, 
(%)b 
HR (95% CI) p-
valuea 
Colistin 
Susceptible 
Resistant 
Imipenem 
Susceptible 
Resistant 
 
10 (35.7) 
0 (-) 
 
2 (100) 
1 (50) 
 
18 (64.3) 
2 (100) 
 
(-) 
1 (50) 
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
Resistance (n=104) 
No drug resistance 
Any drug resistance 
Single drug resistance 
Multi-drug resistance 
 
40 (77) 
25 (48) 
13 (86.7) 
12 (32.4) 
 
12 (23) 
27 (52) 
2 (13.7) 
25 (67.6) 
 
1.0 (reference) 
2.21 (1.12-4.37) 
0.05 (0.11-2.23) 
3.05 (1.53-6.08) 
 
 
0.02 
0.36 
0.001 
HR=hazard ratio. CI=confidence interval. CVL=central venous line. aStatistically significant 
values have been marked in boldface.bPercentages in parentheses are based on the total number 
of each variabel. 
Our overall study population included 104 patients. Due to incomplete medical records n 
decreased in some cases.
Treatment 
Empirical therapy (n=92) 
Appropriate empirical 
therapy 
Inappropriate empirical 
therapy 
Appropriate empirical 
monotherapy 
Inappropriate empirical 
monotherapy 
Appropriate empirical 
combination therapy 
Inappropriate empirical 
combination therapy 
 
 
50 (70.4) 
 
8 (38) 
 
37 (79) 
 
6 (46) 
 
13 (55) 
 
2 (25) 
 
 
21 (29.6) 
 
13 (62) 
 
10 (21) 
 
7 (54) 
 
11 (45) 
 
6 (75) 
 
 
 
1.0 (reference) 
 
2.24 (1.12-4.49) 
 
1.0 (reference) 
 
3.13 (1.16-8.44) 
 
1.0 (reference) 
 
1.67 (0.61-4.53) 
 
 
 
 
 
0.02 
 
 
 
0.02 
 
 
 
0.31 
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3.4 Multivariate analysis 
 
Multivariate analysis using Cox hazard model, demonstrated that multi-drug resistance 
(adjusted HR 3.40 [95% CI 1.28-9.03], p=0.01) is an independent risk factors for all-
cause mortality (Tab.6). 
 
Table 6 - Independent risk factors for all-cause mortality for 104 patients with P. 
aeruginosa BSI according to multivariate analysis using Cox hazard model 
Risk factor HR (95%CI) p-value 
Drug resistance  
No drug resistance 
Multi-drug resistance 
 
1.0 (reference) 
3.40 (1.28-9.03) 
 
 
0.01 
Unknown source of infection 2.24 (0.94-5.30) 0.06 
HR= hazard ratio. CI= confidence interval. .  
 
3.5 Impact of carbapenem resistance on mortality in P. aeruginosa bacteremia 
 
For a more comprehensible presentation, patients with strains resistant to any drug 
except carbapenem were marked as group A, patients with strains resistant to only 
carbapenem as group B and patients with strains resistant to at least two 
antipseudomonal drugs and one carbapenem as group C (Tab. 7).  
Of the 104 patients, there were 17 patients (16.4%) with strains resistant to any 
antipseudomonal drug except carbapenem (group A). 33 patients (31.7%) with P. 
aeruginosa strains that were resistant only to carbapenems (group B) and in 29 cases 
(27.9%) strains were resistant to one carbapenem and at least two other 
antipseudomonal drugs (group C). All-cause hospital mortality rate for patients in group 
A was 35.3% (6/17), whereas mortality rates for group B and C were higher: 60.6% 
(20/33) and 69% (20/29), respectively. In univariate analysis for all-cause mortality, 
group A tended to be associated with mortality, however not statistically significant 
(adjusted HR 1.47 [95% CI 0.55-3.93], p=0.44). Compared to patients without 
carbapenem resistance, patients in group B were significantly associated with mortality 
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(adjusted HR 2.31 [95% CI 1.13-3.98], p=0.02). The same association was observed in 
group C (adjusted HR 2.79 [95% CI 1.36-5.73], p=0.005). When analyzing resistance 
by various drug combinations, our results demonstrate that carbapenem resistance was 
the driving force for mortality 
 
Table 7 - Influence of carbapenem resistance on mortality using univariate analysis 
Resistance by drug 
combination 
No. of 
survivors 
(%) 
No. of 
non-
survivors 
(%) 
HR (95% CI) p-
valuea 
No drug resistance 
Group A: Resistance to any 
antipseudomonal drug except 
carbapenem 
40 (38.5) 
11 (10.6) 
12 (11.5) 
6 (5.8) 
1.0 (reference) 
1.47 (0.55-3.93) 
 
0.44 
No carbapenem resistance 
Group B: Resistance to 
carbapenems 
51 (49.0) 
13 (12.5) 
19 (18.3) 
20 (19.2) 
1.0 (reference) 
2.13 (1.13-3.98) 
 
0.02 
No drug resistance 
Group C: Resistance to 1 
carbapenem and at least 2 other 
antipseudomonal drugs 
40 (38.5) 
9 (8.7) 
12 (11.4) 
20 (19.2) 
1.0 (reference) 
2.79 (1.36-5.73) 
 
0.005 
For a more comprehensible presentation drug resistances were categorized into three groups 
(A-C). a Statistically significant values have been marked in boldface. 
Percentages in brackets are based on our overall study population of 104 patients.  
 
3.6 Survival analysis 
 
The association between inappropriate empirical therapy and resistance was further 
explored by a survival curve.  
Kaplan-Meier survival curve (log-rank p=0.0008) showed that patients receiving 
inappropriate empiric therapy had a lower chance of survival when compared to patients 
receiving appropriate empirical therapy Fig. 1.  
3. Results 
    34 
Kaplan-Meier survival curve (long-rank p=0.5) for drug resistance showed that patients 
without any drug resistance had a higher chance of survival (median survival time=38 
days), compared to patients with a single drug resistance (median survival time=37 
days), followed by patients with multiple drug resistance (median survival time=6 days) 
Fig. 2. 
 
 
The y-axis shows the survival percentage and the x-axis shows survival time in days. n= 101, 
median survival time for ‘appropriate empirical therapy’=30 days, median survival time for 
‘inappropriate empirical therapy’=13 days, median survival time for ‘no empirical therapy’=3 
days; p=0.0014. 
Blue= Appropriate empirical therapy. Red= Inappropriate empirical therapy.  
 
Figure  2 - Kaplan-Meier survival analysis for all-cause hospital mortality according to 
the receipt of empirical antimicrobial therapy (n=101) 
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 The y-axis shows the survival percentage and the x-axis shows survival time in days. n= 
104, median survival time for ‘no drug resistance’=38 days, median survival time for ‘single 
drug resistance’=37 days, median survival time for ‘multidrug resistance’=6 days; p=0.5 
Blue= No drug resistance. Red= Single drug resistance. Green= Multi drug 
resistance. 
 
Figure  3 - Kaplan-Meier analysis for all-cause hospital mortality according to 
antimicrobial resistance (n=104) 
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4. Discussion 
 
This retrospective study, analyzing patients with BSI due to P. aeruginosa in the time 
period of 1st of January 2009 until the 31st of October 2015, sought to determine risk 
factors for BSI due to P. aeruginosa and to investigate the impact of resistance and 
antibiotic therapy on mortality.  
Univariate analysis demonstrated that chemotherapy, neutropenia, unknown source of 
bacteremia, multidrug resistance, carbapenem resistance and inappropriate empirical 
therapy was associated with increased all-cause hospital mortality. Resistance to ≥2 
agents (multidrug resistance) was an independent risk factors for worse outcome. 
 
4.1 Risk factors for BSI due to P. aeruginosa 
 
All-cause hospital mortality was found to be 37.5%. This could be corroborated with 
mortality rates from recently published studies with mortality ranging between 34% and 
almost 60% (118, 130). It is also important to note, that mortality rates may show 
regional variation. 
Identification of risk factors provides several advantages for clinical practice. First of 
all, it helps the physician to identify potentially infected patients more quickly and 
initiate aggressive therapy. It also helps to understand epidemiology and pathogenesis 
of the pathogen.  
Our study did not conclude that older age is a risk factor for mortality. In fact, according 
to our results patients aged 75 or above had a higher chance of survival in comparison 
to younger patients. This finding does not only contradict other studies (118, 131) but 
also clinical understanding that older patients typically bear preexisting comorbidities, 
resulting in higher mortality. In our study, patients in the age group ≥75, out of 20 
patients only 2 (5.1%) died. In comparison to the younger age groups of ≤55, 56-64 and 
65-74, 30.7%, 33.3% and 30.7% died, respectively. This suggests that this subgroup of 
older patients in the study was comparatively healthy. Chamot et al. also unexpectedly 
found older patients to be associated with better survival. The authors concluded that 
lack of predisposing conditions (e.g. no neutropenia, no steroid treatment) of this 
subgroup resulted in a better outcome when compared to younger patients. (132). 
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Indeed, this observation was also applicable to the study-subgroup of older patients, in 
that the surviving older patients were neither neutropenic nor had they received 
chemotherapy in the last 30 days.  
Patients with P. aeruginosa BSI admitted to ICU had a non-statistically significant 1.56 
fold greater likelihood of dying, when compared to patients in medical and surgical 
wards. Patients in the ICU are typically severely ill, have a debilitated immune system, 
often receive corticosteroids and cytotoxic agents, thus making them more susceptible 
to infections with opportunist pathogens such as P. aeruginosa.  
Results from our study also suggest that patients who had been hospitalized in the last 
90 days had a greater risk of dying. This finding almost achieved statistical significance. 
(p=0.06). Previously hospitalized patients may be more severely ill and may have 
received antipseudomonal antibiotics during previous hospital stays. Previous studies 
have identified prior antibiotic therapy as a risk factor for higher mortality in P. 
aeruginosa (133-135). Kollef et al. suggest that prior administration of an antibiotic 
predisposes a patient to colonization with a strain resistant against the previously 
administered antibiotic, therefore leading to increased mortality (136). 
We sought to investigate the impact of medical devices on mortality and concluded that 
endotracheal devices, CVL and nasogastric tube tended to be associated with lower 
survival, however not yielding statistically significant results. Urinary catheters and 
prosthesis tended to be associated with improved outcome, albeit without statistical 
significance.  
Medical devices (e.g. mechanical ventilator, arterial and venous lines, urinary catheter 
etc.) have been established as risk factors for P. aeruginosa BSI (57, 130). They 
predispose to this type of infection, as they disrupt the normal barrier of the human skin 
and are adept to  biofilm-formation on the surface of the devices (137). 
We could identify primary source of BSI in 42 cases, whereas in 45 cases the primary 
source of BSI remained unknown. Of the known primary sources of infection, the 
respiratory tract was the most frequent source of infection. We could not determine 
significant association with higher mortality in the cases of pulmonary source, urinary 
source and line-associated infections. This may be a result of the small numbers of cases 
that could be investigated. Moreover, if the source of infection was unknown patients 
had a 2.45 fold greater risk of dying (p=0.006). This result is in accordance with other 
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studies (118, 122). Patients with unknown source of infection and pulmonary source of 
infection had higher mortality rates than patients with line-associated infections (51% 
vs. 47% vs. 10% respectively). This may indicate that treatment options such as 
removal of potentially infected venous lines are of utmost importance in BSI due to P. 
aeruginosa. Although unknown source of infection was found to be an independent risk 
factor associated with mortality, this needs to be interpreted with caution for our center. 
In many cases physicians did not document the source of infection. These cases were 
thus marked as ‘unknown source of infection’, subsequently leading to reporting-bias. 
Chemotherapy and presence of neutropenia were both significantly associated with 
increased mortality. Neutropenic patients had higher mortality in comparison to non-
neutropenic patients (60% vs. 32%, respectively). Neutropenic patients had a 2.54-fold 
lower chance for survival (p=0.01). Thus, according to our data, neutropenia is a risk 
factor for P. aeruginosa BSI. A previously published study yielded similar results. 
Cattaneo et al.  examined 441 episodes of BSI in patients with underlying hematological 
diseases and found P. aeruginosa to be the only pathogen to be independently 
associated with mortality (138). Kim et al. studied febrile neutropenic adolescents and 
children and noted high mortality of approximately 39% for P. aeruginosa BSI (31). In 
the past years P. aeruginosa and other gram-negative pathogens have been reaching 
high rates of incidence. Interestingly, MDR strains have also been rising alarmingly in 
hematological wards. This may have resulted in increased mortality rates in 
hematological patients (139). Cattaneo and colleagues also suggest the rise of MDR in 
P. aeruginosa may be a result of the widespread use of fluorochinolones as prophylaxis 
in hematological patients (138). 
During extraction of data, the investigator could only evaluate nosocomial or hospital-
acquired infections, as community-acquired infections and healthcare-acquired 
infections are not marked in the patients’ files. Traditionally, community-acquired 
infections are defined as infections that occur within 48 hours of hospital admission. In 
addition, the patient may not have been in contact with healthcare service. Healthcare-
acquired infections also occur within 48 hours of admission. In this case, previous 
contact to healthcare service (also including nursing homes and long-term care 
facilities) is included in the definition (140).  
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4.2 Impact of appropriate versus inappropriate therapy on mortality 
 
Our study demonstrated a statistically significant association between administration of 
inappropriate initial antipseudomonal therapy and all-cause hospital mortality and 
clearly suggest a benefit in survival for patients receiving appropriate empirical therapy.  
When a bloodstream infection is suspected, an antibiotic treatment must be 
administrated within few hours and before the susceptibility profile is known. The 
clinician has to balance preventing death from infection and an unnecessary overuse of 
antibiotics, which would increase resistance rates in healthcare and community settings. 
Superfluous use of antibiotics also increases the risk for adverse events. In addition it 
may have an unfavorable economic impact. Despite high mortality rates for patients 
receiving inappropriate therapy (80, 136, 141), there have been conflicting results on the 
impact of empirical therapy on the outcome mainly due to low quality studies.  
In 1999, Kollef et al. published a study that investigated the effect of inappropriate 
antimicrobial therapy on the outcome of critically ill patients. The authors found 
inappropriate antimicrobial treatment to be the most important independent risk factor 
for higher hospital mortality (adjusted OR 4.26 [95% CI 3.35-5.44], p=≤0.001). 
However, this study did not evaluate the impact specifically for P. aeruginosa BSI 
(136). Several other studies also suggest that appropriate therapy is associated with 
improved survival (142-147). Leibovici et al. examined 3440 patients with bloodstream 
infections in a single-center study and inappropriate empirical treatment was found to 
be an independent risk factor for mortality in multivariate analysis (OR=1.6 [95% CI 
1.0-2.5]). Benefit for survival could be seen in patient groups with good (young, no 
underlying disease) and bad (advanced age, with low functional capacity) prognosis. 
When treated with inappropriate empirical therapy, risk for fatality was highest for 
Klebsellia pneumoniae (OR=3.0 [95% CI 1.7-5.1]). Risk for fatality for P. aeruginosa 
was lower in comparison (OR=1.2 [95% 0.7-1.9]). In this study, empirical therapy was 
deemed appropriate when the pathogen was found to be susceptible in vitro to the agent. 
The authors highlighted the importance of conducting future studies with more specific 
definitions, as more factors (e.g. route of administration, dosage) influence 
appropriateness (145). Several other studies found an association between inappropriate 
empirical therapy and mortality (142-144), however they did not focus exclusively on 
P. aeruginosa BSI.  
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Micek et al. conducted a single-center study in Israel and retrospectively examined the 
impact of appropriate empirical therapy on 305 patients with BSI due to P. aeruginosa. 
The authors of this large-scale study found inappropriate empirical treatment to be an 
independent prognostic factor for hospital mortality (146). Appropriate initial therapy 
was defined as the antipseudomonal agent to which the strain was susceptible in vitro. 
Their analysis also showed that administering a combination therapy as empirical 
treatment increased the chance of receiving appropriate therapy.  
Two recently published studies suggested that appropriate empirical therapy only 
significantly improved survival in specific subgroups of patients. In a multicenter study 
conducted in Israel, Schechner et al. examined the impact of therapy on in-hospital 
mortality in patients with P. aeruginosa BSI upon hospital admission. Multivariate 
analysis showed that inappropriate initial therapy was associated with increased risk of 
death only in patients with severe sepsis or septic shock (OR= 1.8, p=0.051). In 
univariate analysis, inappropriate initial treatment tended to be associated with mortality 
in patients without severe sepsis of septic shock, however without statistical 
significance (122). Kang et al. examined a total of 286 patients with BSI caused by 
gram-negative resistant strains, including 74 patients with P. aeruginosa BSI. Their data 
showed an association between inappropriate empirical therapy and mortality in patients 
with lung-associated bacteremia, peritoneum-associated bacteremia and when source of 
bacteremia was unknown (high-risk source) and no association with pancreaticobiliary-
associated, urinary tract associated and catheter-related bacteremia (low-risk source) 
(133). Two studies yielded similar results (80, 147). Results from another study 
conducted by Kang et al. suggested that a delay in appropriate empirical therapy for 
patients with P. aeruginosa infections of the pancreaticobiliary tract did not deteriorate 
survival significantly (147). Vidal et al. established that inappropriate empirical therapy 
influenced outcome in patients with P. aeruginosa BSI only when intravenous line-
associated infections were excluded from analysis (80). These reports not only highlight 
the importance of treatment options such as surgical decompression of obstruction or 
removal of infected venous lines, but also that empirical antipseudomonal therapy is 
beneficial for patients presenting severe illness (e.g. septic shock) and when high-risk 
sources of bacteremia are involved.  
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Other studies failed to find an association between inappropriate empirical therapy and 
lower survival (121, 148). In a single-center study Zaragoza and colleagues (148) 
prospectively examined the impact of inappropriate empirical therapy on ICU-patients 
with BSI due to various pathogens. Of the 166 patients, only two patients with P. 
aeruginosa infections had received inappropriate emipirical therapy. They could not 
establish an association between inadequacy and mortality. Nonetheless, the authors 
emphasized the low prevalence of patients with pulmonary-associated infections and 
abdominal-associated infections (high-risk source of infection) that had been treated 
inadequately. In addition, the study included various pathogens. Osih et al. (121) also 
examined the impact of adequate empirical therapy on 167 patients with BSI due to P. 
aeruginosa. They studied adequate empirical therapy at three different time points, in 
order to clearly distinguish between empirical and definitive therapy. The authors 
argued that it is difficult to clearly distinguish between empirical and definitive therapy 
retrospectively, for in many cases the clinician changes antimicrobial agents during 
therapy according to preliminary blood culture results. However, this therapy regimen 
cannot be labeled as definitive therapy. This is only true for agents that have been 
applied according to final susceptibility results. Therefore, the authors examined 
therapies that were applied in the time frame of (i) 24h and (ii) 24h-48h after blood 
cultures were drawn and (iii) after susceptibility results were known. They also assessed 
severity of illness at a time point 24h before the first blood culture was collected, thus 
assessing severity of illness at a time before presentation of bacteremia. This allowed 
them to properly control for severity of illness as a predictor for mortality. Their results 
showed a non-statistical significant trend towards decreasing mortality and length of 
stay for appropriate empirical therapy but no clear benefit for survival could be found. 
However, it is essential to point out that the authors did not exclude polymicrobial 
infections and could not assure that these infections were appropriately treated as well, 
subsequently influencing mortality.  
Our study clearly suggests an association between inappropriate empirical therapy and 
increased mortality and these results are consistent with those of a meta-analysis 
published in 2010. Paul et al. (149) reviewed prospective studies that examined the 
effect of appropriate empirical therapy on all-cause mortality in patients with sepsis. 
Although the authors could determine an association between appropriate empirical 
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therapy and improved outcome, the OR ranged from 0-15, pointing to a highly variable 
effect on mortality. The studies were heterogeneous in nature, in patient populations, in 
types of infections and microorganisms. Most importantly, definitions for adequacy of 
empirical were not identical. The authors emphasized the need for new studies 
employing uniform methodologies. McGregor and colleagues examined study methods 
used to assess the benefit of appropriate empirical therapy (150). The authors made 
several suggestions to improve designs of future studies: i) Definition for 
appropriateness should not only include in vitro susceptibility but also dosage, route and 
pattern of administration. ii) Empirical and definitive treatment should be examined 
separately. iii) To avoid confounding effects on mortality, severity of illness should be 
assessed before onset of bacteremia. iv) Mortality should be defined more specifically 
(e.g. 30-day mortality (149)).   
 
4.3 Monotherapy versus combination therapy 
 
In our study, we also attempted to examine the impact of antipseudomonal monotherapy 
versus combination therapy on mortality. There are several arguments supporting the 
administration of combination therapy (Tab. 8). It is suggested that a higher killing rate 
may be achieved by synergism between antibiotics (76, 151, 152). It has been shown 
that bactericidal activity of antipseudomonal β-lactam agents may be enhanced by an 
addition of an aminoglycoside (151). Additionally, combination therapy may lower the 
risk of receiving inappropriate therapy (146). It has also been suggested that the use of 
combination therapy may reduce the risk of emergence of resistance (153). On the other 
hand, monotherapy may be associated with lower risk for adverse events, especially 
when aminoglycosides are avoided (154). Also emergence of fungal superinfections and 
increased costs may be a disadvantage of combination therapy (155).  
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Table 8 - Potential advantages and disadvantages for combination therapy in P. 
aeruginosa BSI 
Advantages Disadvantages 
Lower risk for administration of 
inappropriate empirical 
Increased costs 
 
Lower risk for emergence of resistance Increased risk for superinfection 
Possible synergism Increased risk for drug toxicity 
 
Patients receiving appropriate empirical combination therapy showed higher mortality 
rates than the patients who received appropriate empirical monotherapy (45% vs. 21%, 
n=24 vs. n=47, respectively). When considering mortality rates, monotherapy is 
favorable to combination therapy as empirical treatment. However, a comparison of 
monotherapy to combination therapy may lead to skewed results, for clinicians may 
treat severely ill patients with worse outcome more frequently with combination 
therapy. This may explain higher mortality rates for empirical combination therapy in 
our study. Peña and colleagues have highlighted this aspect in displaying that 
combination therapy was more frequently administered in high-risk sources of 
bacteremia and when clinical presentation was severe (156).  
Observational studies examining the impact of combination therapy have yielded 
conflicting results. To the best of my knowledge, Peña et al. conducted the largest 
cohort-study of 593 patients with P. aeruginosa bacteremia in regard to 
antipseudomonal therapy. Antipseudomonal therapy was classified as appropriate when 
the strain matched in vitro susceptibility and pattern of administration and dosage were 
in line with medical standards. The authors could not identify a survival benefit for 
combination therapy during empirical or definitive treatment. Howbeit, the authors 
included different combination regimens (e.g. β-lactam and aminoglycoside, colistin 
and aminoglycoside). It is therefore not possible to examine the impact of synergism, 
for synergistic interactions might be class dependent (156). Bowers et al. conducted an 
international, multicenter study where 384 patients were included in order to study the 
impact of appropriate empirical combination therapy on outcome (157). According to 
their data, no survival difference for empirical combination or monotherapy could be 
found. Chamot et al. included a cohort of 115 patients with bacteremia due to P. 
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aeruginosa, showing lower survival for patients receiving appropriate empirical 
monotherapy (adjusted HR, 3.7 [95% CI, 1.0-14.1]) (132).  
It is difficult to compare results from observational studies. First and foremost, authors 
take different definitions for adequacy of treatment into account. As mentioned before, 
it is problematic to make predictions on synergism when different types of combination 
therapies are included in one study. Some studies accepted aminoglycosides as an 
appropriate therapy regimen (141, 158). However aminoglcoside monotherapy for P. 
aeruginosa is not recommended except in the case of UTI. In addition, study 
populations are variable in comorbidities and severity of underlying diseases and small 
cohort sizes can lead to a diminished statistical validity. In order to compensate for 
small sample sizes, several authors have conducted meta-analyses to study the impact of 
combination and monotherapy on survival. Paul et al. (159) reviewed 7863 sepsis 
patients from various studies to examine whether β-lactam-aminoglycoside combination 
therapy was superior to β-lactam monotherapy. The authors did not find an advantage 
for combination therapy. Moreover, they found an increase in renal damage when 
combination therapy was administered. However, the soubgroup of P. aeruginosa 
patients was underpowered to show an effect. A second meta-analysis, conducted by 
Vardakas and colleagues, investigated the effect of β-lactam-aminoglycoside or 
fluorochinolone combination therapy and that of β-lactam monotherapy in P. 
aeruginosa infections on outcome. In total, 174 patients were included. The authors 
could not determine a benefit for combination therapy, neither for β-lactam and 
fluorochinolone nor for β-lactam and aminoglycoside (120). 
To date presumed advantages for combination therapy remain questionable. Several 
investigators suggest in vitro synergism between drugs for improved outcome (151). 
However, these results could not be confirmed in in vivo studies (79). The assertion that 
application of combination therapy increases the chance for appropriate therapy has 
been examined by Micek and colleagues (146) and needs to be confirmed in future 
studies. It is plausible to conclude that combination therapy may reduce the risk for 
resistance, for this is true for other infectious diseases such as tuberculosis (160). 
However, there is no clear evidence for P. aeruginosa infections (161, 162). In contrast, 
a recently published study suggested that combination therapy for P. aeruginosa 
infections might select for broad-spectrum resistance (163). As mentioned above, Paul 
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and colleagues identified an increased risk for renal damage for combination therapy 
with an aminoglycoside in sepsis patients (161). Another meta-analysis examining 
combination therapy in cancer patients with neutropenia yielded similar results: drug 
toxicity was associated with combination therapy, specifically leading to an increase in 
renal damage (164). In addition, antipseudomonal empirical therapy is also applied to 
patients that may not be infected with P. aeruginosa, thus exposing this subgroup of 
patients to an unnecessary risk for drug toxicity.  
In regard to the factors mentioned above and taking the results of my study into 
consideration, there is no clear benefit for combination therapy in P. aeruginosa 
bacteremia. More observational studies with larger study groups, precise and 
concordant definitions are needed to examine whether combination therapy is superior 
to monotherapy. Additionally, apart from mortality, outcomes should also include 
emergence of resistance, adverse events and development of bacterial and fungal 
superinfections. 
 
4.4 Carbapenem resistance  
 
In our cohort of 104 patients with P. aeruginosa BSI, carbapenem resistance was 
significantly associated with increased all-cause mortality. Patients with a carbapenem-
resistant strain had a 2.13 fold higher chance of dying (p=0.02) than patients with 
carbapenem-susceptible strains. To further explore this association, we added further 
resistances to the analysis of carbapenem resistance (Group C) and found that the rates 
for mortality were similar to those for carbapenem resistance and that the impact on 
outcome did not differ substantially (Tab. 7). This observation emphasizes the impact 
of carbapenem resistance on mortality for patients with P. aeruginosa BSI. In contrast 
to non-resistant strains, having any drug resistance except carbapenem did not have a 
significant impact on mortality. Our data therefore clearly suggests a significant 
influence of carbapenem resistance on mortality.  
Carbapenems are potent drugs of choice against serious P. aeruginosa infections but 
alarmingly high prevalence of carbapenem resistance worldwide (165, 166) is 
threatening their role as drug of choice for MDR P. aeruginosa infections (167). The 
detrimental impact of antimicrobial resistance on patient outcomes such as length of 
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hospital stay and rising economic costs have been established (168). Nonetheless, the 
impact of carbapenem resistance on mortality has been questioned (87, 169).  
Suarez et al. retrospectively compared 88 episodes of carbapenem-resistant strains to 33 
episodes of carbapenem-susceptible strains in patients with P. aeruginosa bacteremia 
(169). The authors discovered similar attributable mortality (33% vs. 30%, p=0.69) and 
interestingly, initial slower deaths for patients with carbapenem resistance. The authors 
explained this association with a potential lower virulence of resistant strains, for there 
has been some in vitro evidence of a more damaging immune response when infection 
with susceptible P. aeurginosa strains occurred (170). As the former study is 
retrospective in nature and the small cohort size may have influenced lower statistical 
power for attributal mortality, the results should be treated with caution. In a 
prospective multicenter study 638 episodes of P. aeruginosa BSI were analyzed and 
although the authors could find a significant association between carbapenem resistance 
and mortality, this effect was not as detrimental in the first days of infection (87). To 
date, the complex interactions between resistance and bacterial fitness remain unclear 
and need to be further explored (171).  
A recently published meta-analysis that included 6660 patients with P. aeruginosa 
infections found a significant association between carbapenem-resistant P. aeruginosa 
and higher mortality, in both univariate and multivariate analysis.  
In regard to our results there is evidence for an association between carbapenem 
resistance and increased mortality in P. aeruginosa infections.  
Several studies have investigated risk factors for carbapenem resistance in P. 
aeruginosa BSI. Prior carbapenem exposure and medical devices were found to be 
strong risk factors for carbapenem resistance (172, 173). As incidence of MDR P. 
aeruginosa infections is on the rise (43), MDR infections have been associated with an 
increase in mortality, morbidity and economic costs (174). Tumbarello et al. found 
MDR to be an independent risk factor for mortality in patients with P. aeruginosa BSI 
and prior use of antibiotics as a risk factor for MDR (175). In a systematic review 
Falagas and colleagues established prior carbapenem use as one of the main risk factors 
for MDR in  P. aeruginosa (176). 
It is also important to point out that mechanisms of resistance of the clinical isolates of 
P. aeruginosa were not available to us and our results may not be applicable to other 
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centers, as there can be differences in resistance mechanisms leading to different 
resitance phenotypes. 
In light of these results it seems important that hospital stewardship programs target 
usage of carbapenems to reduce the spread of resistant strains and reduce overall 
mortality associated with severe infections due to MDR gram negatives.  
 
4.5 Conclusion 
 
This retrospective study shows high mortality rates for patients with P. aeruginosa BSI.  
Infection with P. aeruginosa resistant to two or more antipseudomonal agents 
(multidrug resistance) was a risk factor for mortality in BSI. We could not find a 
survival benefit for combination therapy. 
On the basis of the results of this study, empirical therapy of BSI in patients with risk 
factors for gram-negatives etiology needs to include at least one antibiotic active against 
P. aeruginosa based on local resistance rates and settings. 
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Background: 
Pseudomonas aeruginosa is one of the most prevalent causes for bloodstream infections 
due to gram-negative bacteria, resulting in high mortality rates, especially in patients 
with severe underlying disease. In addition to its intrinsic resistance, this pathogen 
acquires resistance rapidly. Currently the resistance rates in P. aeruginosa are rapidly 
increasing in hospitalized patients worldwide. Of even more concern, the increase in the 
incidence of multidrug resistant strains leaves very few treatment options.  
Methods: 
In our study we sought to define overall mortality rate and risk factors associated with 
mortality in bloodstream infections due to Pseudomonas aeruginosa. Secondary 
outcomes were the mortality rates according to appropriateness of antipseudomonal 
therapy, combination versus monotherapy, and presence of multidrug resistance defined 
as resistance to at least two antipseudomonal agents. 
We conducted a retrospective cohort study in the University Hospital of Tübingen of 
inpatients with bloodstream infections due to Pseudomonas aeruginosa between 
January 2009 and October 2015. We collected epidemiological, medical and 
microbiological data from medical records and analyzed the data using survival 
analysis. Univariate and multivariate analysis was performed using Cox proportional 
hazard model.  
Results: 
The final cohort comprised 104 patients with Pseudomonas aeruginosa bloodstream 
infections. Overall all-cause hospital mortality was 37.5 %. Univariate risk factor 
analysis showed factors, which significantly increased mortality: chemotherapy 
(adjusted HR 2.12 [95% CI 1.0-4.5], p=0.04), neutropenia (adjusted HR 2.54 [95% CI 
1.25-5.18], p=0.01), unknown source of infection (adjusted HR 2.45 [95% CI 1.28-
4.69], p=0.006) and multidrug resistance (adjusted HR 3.05 [95% CI 1.53-6.08], 
p=0.001). Empirical inappropriate treatment was significantly associated with poor 
outcome (adjusted HR 2.24 [95% CI 1.12-4.49], p=0.02). All-cause mortality for 
patients receiving appropriate empirical monotherapy, inappropriate empirical 
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monotherapy, appropriate empirical combination therapy and inappropriate empirical 
combination therapy were 21% (10/47), 53% (7/13), 45% (11/24) and 75% (6/8) 
respectively. Carbapenem resistance was significantly associated with mortality in 
univariate analysis (adjusted HR 2.13 [95% CI 1.13-3.98], p=0.02). 
Multivariate analysis demonstrated that multidrug resistance (adjusted HR 3.40 [95% 
CI 1.28-9.03], P=0.01) were independent risk factors for mortality.  
Conclusion 
The data show that BSI due to P. aeruginosa is still associated with mortality. Major 
risk factor for mortality is infection with a strain resistant to two or more 
antipseudomonal agents. The study does not show a benefit for combination therapy on 
survival. These data contribute to the existing evidence on impact of empirical therapy 
on mortality of patients with BSI due to P. aeruginosa and provide important 
information for hospital stewardship.
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6. Zusammenfassung 
 
Hintergrund: 
Pseudomonas aeruginosa zählt zu den häufigsten Ursachen einer gram-negativ 
bedingten bakteriellen Sepsis. Hohe Mortalitätszahlen sind besonders bei Patienten mit 
schweren Grunderkrankungen zu verzeichnen. Charakteristisch für das Bakterium ist 
nicht nur die hohe intrinsiche Antibiotikaresistenz, sondern auch die Fähigkeit 
zusätzlich Resistenzmechanismen zu erlangen. Die weltweit steigenden Resistenzraten, 
insbesondere die der multiresistenten Stämme, erschweren eine adäquate Therapie 
hospitalisierter Patienten. 
Methodik: 
Im Rahmen dieser Dissertation wurden die Gesamtmortalität und Risikofaktoren von 
Patienten mit einer durch das Pseudomonas aeruginosa Bakterium verursachte Sepsis 
untersucht. Als sekündäre Zielvariabeln wurde die Mortalität in Bezug auf adäquate 
antimikrobielle Therapie, antimikrobielle Kombinations- bzw. Monotherapie und 
Multiresistenz (definiert als Resistenz gegen mindestens zwei Pseudomonas-wirksame 
Antibiotika) untersucht. 
In die retrospektive Kohortenstudie wurden Patienten eingeschlossen, die sich im 
Zeitraum Januar 2009 bis Oktober 2015 in stationärer Behandlung am 
Universitätsklinikum in Tübingen befanden. Es wurden epidemiologische, medizinische 
und mikrobiologische Daten aus den Patientenakten erhoben und im Rahmen einer 
Ereigniszeitanalyse wurde das Cox-Regressionsmodell zur uni- und multivariaten 
Analyse der Daten herangezogen. 
Ergebnisse: 
Insgesamt konnten Daten von 104 Patienten mit einer Pseudomonas aeruginosa 
Blutstrominfektion analysiert werden. Die Gesamtmortalität der Kohorte betrug 37.5 %. 
Die univariate Analyse zeigte einen signifikanten Zusammenhang zwischen der 
Mortalität und folgenden Risikofaktoren: Chemotherapie (adjusted HR 2.12 [95% CI 
1.0-4.5], p=0.04), Neutropenie (adjusted HR 2.54 [95% CI 1.25-5.18], p=0.01), 
unbekannte Infektionsquelle (adjusted HR 2.45 [95% CI 1.28-4.69], p=0.006), 
Multiresistenz (adjusted HR 3.05 [95% CI 1.53-6.08], p=0.001) und inadäquate 
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empirische Antibiotika-Therapie (adjusted HR 2.24 [95% CI 1.12-4.49], p=0.02). Die 
Gesamtmortalität für Patienten mit einer adäquaten empirischen Monotherapie, einer 
inadäquaten empirischen  Monotherapie, einer adäquaten empirischen 
Kombinationstherapie und einer inadäquaten empirischen Kombinationstherapie waren 
wie folgt: 21% (10/47), 53% (7/13), 45% (11/24) and 75% (6/8).  
Die multivariate Datenanalyse konnte Multiresistenz (adjusted HR 3.40 [95% CI 1.28-
9.03], P=0.01) als einen unabhängigen Risikofaktor für erhöhte Mortalität feststellen. 
Zusammenfassung: 
Die Ergebnisse der Analyse heben die hohe Mortalität für Sepsis durch Pseudomonas 
aeruginosa hervor. Stämme mit mindestens zwei Resistenzen stellen den 
Hauptrisikofaktor für erhöhte Mortalität dar. Die Studie kann keine therapeutische 
Überlegenheit einer antimikrobiellen Kombinationstherapie gegenüber einer 
Monotherapie feststellen.  
Die Ergebnisse unterstützen die bisherige Beweislage für die Auswirkung von 
empirischer Antibiotikatherapie auf die Mortalität für Patienten mit einer Pseudomonas 
aeruginosa Sepsis und liefern wichtige Daten für das Verständnis einer rationalen 
Antibiotikaanwendung („Antibiotic Stewardship“). 
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